Skip to main navigation Skip to search Skip to main content

Are clinical guidelines for the management of intraductal papillary mucinous neoplasms followed? A single-center analysis

  • Parissa Tabrizian*
  • , Yaniv Berger
  • , Elisa Sefora Pierobon
  • , Samantha Aycart
  • , Pamela Argiriadi
  • , Kezhen Fei
  • , Gonzalo Carrasco-Avino
  • , Daniel M. Labow
  • , Umut Sarpel
  • *Corresponding author for this work
  • Icahn School of Medicine at Mount Sinai

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Objectives: This study aimed to determine how frequently guidelines for the management of intraductal papillarymucinous neoplasms (IPMNs) are followed and establish factors associated with failure. Methods: Four hundred forty-five patientswith radiographic diagnosis of IPMN 1 cm or greater between January 1, 2003 and January 1, 2013 were included. We defined failure of guideline adherence if the following occurred: (a) failure of acknowledgment of IPMN, (b) failure to undergo endoscopic ultrasound, (c) failure to undergo resection, or (d) failure to undergo at least 1 surveillance image within 2 years after diagnosis. Results: Failure of guideline adherence was observed in 58% of patients and evident across all the respective criteria (A: 38%, B: 25%, C: 29%, D: 33%). Age older than 68 years (P < 0.01), American Society of Anesthesiologists score of 3 or higher (P < 0.0001), benign findings on imaging (P < 0.0001), and major comorbid conditions (P < 0.01) were factors associated with higher rate of failure to compliance. On multivariate logistic regression, American Society of Anesthesiologists score of 3 or higher and benign features were associated with 4.0 times (95% confidence interval, 2.02-8.06) and 2.6 times (95% confidence interval, 1.60-4.07) higher odds of failure to compliance with guidelines, respectively. Conclusions: Compliance with clinical guidelines for the management of IPMN is poor. Socioeconomic factors do not seem to create a disparity to care. However, many patients with IPMN have other medical diagnoses that take priority over IPMN surveillance and treatment.

Original languageEnglish
Pages (from-to)198-202
Number of pages5
JournalPancreas
Volume46
Issue number2
DOIs
StatePublished - 2017
Externally publishedYes

Funding

FundersFunder number
National Cancer InstituteP30CA196521

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 10 - Reduced Inequalities
      SDG 10 Reduced Inequalities

    Keywords

    • Clinical guidelines
    • Intraductal papillary mucinous neoplasms
    • Management
    • Socioeconomic disparity

    Fingerprint

    Dive into the research topics of 'Are clinical guidelines for the management of intraductal papillary mucinous neoplasms followed? A single-center analysis'. Together they form a unique fingerprint.

    Cite this